liposomal daunorubicin-cytarabine Vyxeos
Selected indexed studies
- EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. (Oncologist, 2020) [PMID:32282100]
- Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study. (Int J Hematol, 2025) [PMID:40815417]
- Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. (Drugs, 2018) [PMID:30511323]
_Worker-drafted node — pending editorial review._
Connections
liposomal daunorubicin-cytarabine Vyxeos is a side effect of
Sources
- Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. (2018) pubmed
- EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. (2020) pubmed
- Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study. (2025) pubmed
- Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes. (2021) pubmed
- Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. (2021) pubmed
- AML: New Drugs but New Challenges. (2020) pubmed
- CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. (2020) pubmed
- Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail. (2019) pubmed
- Recognizing the potential for copper-related toxicities from liposomal daunorubicin--cytarabine. (2021) pubmed
- Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). (2021) pubmed